A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy

C. A. Morton (Lead / Corresponding author), R. Dominicus, P. Radny, T. Dirschka, A. Hauschild, U. Reinhold, R. Aschoff, M. Ulrich, S. Keohane, S. Ekanayake-Bohlig, S. Ibbotson, R. Ostendorf, C. Berking, D. Gröne, H. J. Schulze, H. M. Ockenfels, V. Jasnoch, H. Kurzen, M. Sebastian, H. StegeP. Staubach-Renz, F. Hübinger, F. Hübinger, I. Ziabreva, B. Schmitz, A. Gertzmann, H. Lübbert, R. M. Szeimies

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)
185 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences